Every Hayes clinical evidence report is developed by experienced teams that have been trusted by healthcare decision makers since 1989. Here is a sampling of our content that is being used every day to inform defensible, evidence-based decisions by payers and providers.
Not all reports are available for public preview. For more information, please contact us.
Focus of the Report: This report focuses on occipital nerve stimulation (ONS) for treatment of chronic cluster headache (CH) that has failed to respond to available drug treatments.
Technology Description: ONS involves electrical stimulation of the greater and/or lesser occipital nerve…
Focus of the Report: This report focuses on myocardial strain imaging (MSI) using speckle-tracking echocardiography for diagnosis and prognosis in patients who have dilated cardiomyopathy (DCM).
Technology Description: MSI involves a sophisticated analysis of images from echocardiogr…
Focus of the Report: The use of minimally invasive sacroiliac joint (SIJ) fusion with cylindrical threaded implants (CTIs) for the treatment of adults with SIJ dysfunction who have not experienced adequate relief from nonsurgical management (NSM). Evaluation of minimally invasive SIJ fusion using triangular titanium implants (i.e., iFuse Impl…
Viltepso (viltolarsen) is an intravenously administered antisense oligonucleotide indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping.
Casimersen is an investigational intravenously administered antisense oligonucleotide proposed for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping.
Focus of the Report: This report evaluates the use of voretigene neparvovec-rzyl (Luxturna) for the treatment of vision loss due to inherited retinal dystrophies (IRDs) from confirmed biallelic RPE65 mutations.
Technology Description: Voretigene neparvove…
Focus of the Report: This report focuses on amniotic allograft (AA) for treatment or prevention of tendon and ligament injuries.
Technology Description: AA is prepared from sheets of amniotic membrane obtained shortly after caesarean delivery. For some products, amniotic membrane is de…
Berotralstat is an oral plasma kallikrein inhibitor for prevention of hereditary angioedema attacks.
Retevmo (selpercatinib) is a novel oral highly selective RET inhibitor indicated for the treatment of adult patients with metastatic RET fusion-positive non-small cell lung cancer (NSCLC).
Lisocabtagene maraleucel (liso-cel) is an investigational, autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is proposed to treat adults with relapsed or refractory large B-cell lymphoma after at least 2 prior therapies.